Brokerages Anticipate VBI Vaccines Inc (NASDAQ:VBIV) to Post -$0.06 EPS

Wall Street brokerages forecast that VBI Vaccines Inc (NASDAQ:VBIV) will post ($0.06) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for VBI Vaccines’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.07). VBI Vaccines reported earnings per share of ($0.28) during the same quarter last year, which suggests a positive year-over-year growth rate of 78.6%. The company is scheduled to issue its next earnings report on Monday, February 24th.

According to Zacks, analysts expect that VBI Vaccines will report full-year earnings of ($0.47) per share for the current financial year, with EPS estimates ranging from ($0.48) to ($0.45). For the next financial year, analysts forecast that the company will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.21) to ($0.15). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.02). VBI Vaccines had a negative net margin of 1,458.97% and a negative return on equity of 70.54%. The firm had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.90 million.

Several equities research analysts recently issued reports on VBIV shares. Raymond James started coverage on shares of VBI Vaccines in a research note on Thursday, November 14th. They issued an “outperform” rating and a $3.00 target price for the company. ValuEngine downgraded shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Saturday, December 21st. Finally, BidaskClub upgraded shares of VBI Vaccines from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $3.81.

NASDAQ:VBIV traded down $0.15 during mid-day trading on Friday, hitting $1.63. The stock had a trading volume of 6,619,796 shares, compared to its average volume of 7,811,935. VBI Vaccines has a twelve month low of $0.47 and a twelve month high of $2.20. The company’s 50 day simple moving average is $1.19 and its 200 day simple moving average is $0.79. The company has a current ratio of 1.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01.

A number of large investors have recently modified their holdings of the stock. Perceptive Advisors LLC lifted its stake in VBI Vaccines by 8.4% in the 2nd quarter. Perceptive Advisors LLC now owns 25,951,556 shares of the biopharmaceutical company’s stock valued at $24,607,000 after purchasing an additional 2,000,000 shares during the last quarter. BlackRock Inc. lifted its position in VBI Vaccines by 2,089.1% during the second quarter. BlackRock Inc. now owns 4,224,285 shares of the biopharmaceutical company’s stock worth $4,943,000 after acquiring an additional 4,031,318 shares during the last quarter. State Street Corp lifted its position in VBI Vaccines by 4.3% during the third quarter. State Street Corp now owns 1,495,738 shares of the biopharmaceutical company’s stock worth $705,000 after acquiring an additional 61,829 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in VBI Vaccines by 6.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 1,437,549 shares of the biopharmaceutical company’s stock worth $1,682,000 after acquiring an additional 92,930 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in VBI Vaccines by 12.4% during the second quarter. Vanguard Group Inc. now owns 1,356,944 shares of the biopharmaceutical company’s stock worth $1,587,000 after acquiring an additional 149,690 shares during the last quarter. Institutional investors and hedge funds own 41.06% of the company’s stock.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Read More: What is a capital gain?

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.